MONTVALE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations, will present at the conference. About Balchem CorporationBalchem Corpo ...

MONTVALE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025. Ted Harris, Chairman of the Board, President and Chief Executive Officer, Martin Bengtsson, Chief Financial Officer, and Allison Baurichter, Senior Director Investor Relations, will present at the conference. About Balchem Corporation Balchem Corp ...

Core Insights - The article focuses on the Asia Value & Moat Stocks research service, which targets value investors looking for significant discrepancies between stock prices and intrinsic values, particularly in the Asian market [1] Group 1: Investment Strategy - The service emphasizes deep value balance sheet bargains, such as net cash stocks, net-nets, low price-to-book (P/B) stocks, and sum-of-the-parts discounts [1] - It also highlights wide moat stocks, which are characterized by strong earnings power at discounted prices, including high-quality businesses and hidden champions [1] Group 2: Market Focus - The primary focus of the investment ideas is on stocks listed in Asia, with a particular emphasis on the Hong Kong market [1] - The service provides a range of watch lists with monthly updates to assist investors in identifying potential opportunities [1]

Core Insights - Balchem Corporation, a significant player in the specialty chemicals industry, reported record third-quarter sales despite a challenging year, leading to a 5% rise in stock price [1][6] Financial Performance - On October 21, 2025, Balchem reported earnings per share (EPS) of $1.23, missing the estimated $1.36, which represents a slight negative earnings surprise of -0.74%. However, this EPS shows growth compared to the previous year's $1.03 [2] - The company's revenue reached $267.6 million, surpassing the estimated $258.3 million, marking an 11.5% increase from last year's $239.94 million [2] Valuation Metrics - Balchem's price-to-earnings (P/E) ratio is 34.56, indicating strong investor confidence in future earnings [3][6] - The price-to-sales ratio stands at 5.05, reflecting the market's valuation of its revenue [3] - The enterprise value to sales ratio is 5.17, suggesting a strong market valuation relative to sales [3] - The enterprise value to operating cash flow ratio is 26.00, providing insight into its valuation concerning cash flow from operations [4] - The earnings yield is 2.89%, showing the percentage of each dollar invested that was earned [4] - The debt-to-equity ratio is low at 0.15, indicating conservative debt use [4][6] Liquidity and Cash Flow - Balchem's current ratio of 2.72 suggests a strong ability to cover short-term liabilities with short-term assets [5] - The company generated $51 million in free cash flow, which helped reduce debt [5] Market Sentiment - Despite the positive financial performance, Balchem's stock has remained relatively stagnant, indicating that investors are anticipating further results [5][6]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 1-13648 _____________________________________________________________________________________________________________ ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Group 1 - Balchem reported quarterly earnings of $1.35 per share, missing the Zacks Consensus Estimate of $1.36 per share, but showing an increase from $1.03 per share a year ago, resulting in an earnings surprise of -0.74% [1] - The company posted revenues of $267.56 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.92%, compared to year-ago revenues of $239.94 million [2] - Over the last four quarters, Balchem has surpassed consensus revenue estimates three times, indicating a generally positive trend in revenue performance [2] Group 2 - Balchem shares have underperformed the market, losing about 7.5% since the beginning of the year, while the S&P 500 has gained 14.5% [3] - The current consensus EPS estimate for the coming quarter is $1.35 on revenues of $265.69 million, and for the current fiscal year, it is $5.20 on revenues of $1.03 billion [7] - The Zacks Industry Rank for Chemical - Specialty is currently in the bottom 30% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8]

Key Points Balchem reported record third-quarter sales. The company is growing sales while also supporting new growth initiatives. 10 stocks we like better than Balchem › Many people may not know Balchem (NASDAQ: BCPC). The company works to find solutions to problems facing the nutrition, health, and food markets. The human and animal nutrition product company just reported record third-quarter sales, and the stock is jumping today. Balchem shares rose over 5% this morning and remained higher by 3 ...

Financial Data and Key Metrics Changes - The company reported record quarterly consolidated revenue of $268 million, an increase of 11.5% year-over-year [10][11] - GAAP earnings from operations reached $55 million, up 13.7% compared to the prior year [11][14] - Consolidated net income was $40 million, reflecting a 19.1% increase from the previous year, translating to diluted net earnings per share of $1.24, up 20.4% [11][16] - Adjusted EBITDA was a record $71 million, an increase of 11% year-over-year, with an adjusted EBITDA margin rate of 26.7% [11][15] Business Line Data and Key Metrics Changes - The Human Nutrition and Health segment generated record sales of $174 million, up 14.3% from the prior year, with earnings from operations increasing by 14.8% to $41 million [17][18] - The Animal Nutrition and Health segment reported sales of $56 million, a 6.6% increase year-over-year, with earnings from operations rising by 5.2% to $4 million [18][19] - The Specialty Products segment achieved sales of $36 million, a 7.5% increase, with earnings from operations growing by 9.7% to $12 million [20][21] Market Data and Key Metrics Changes - The company noted healthy demand across most end markets, particularly in the Human Nutrition and Health segment, driven by trends towards nutrient-dense and better-for-you foods [3][4] - The Animal Nutrition and Health segment saw improved demand in both monogastric and ruminant businesses, particularly in the European market [4][19] - Specialty Products experienced growth driven by higher demand in performance gases and successful geographic expansion in plant nutrition [5][20] Company Strategy and Development Direction - The company is focused on expanding its marketing efforts and scientific research to bolster its Human Nutrition and Health segment [6][9] - There is a commitment to geographic expansion in the Specialty Products segment, particularly in Latin America and Asia Pacific [20][56] - The company is actively pursuing strategic M&A opportunities while managing debt repayment and maintaining a strong cash flow [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth outlook, citing the ability to manage through macroeconomic challenges and tariff-related impacts [23] - The company is well-positioned to leverage better-for-you trends in health and nutrition markets, expecting continued growth in its Human Nutrition and Health segment [23][18] - Management highlighted the importance of ongoing scientific research and product development to address market needs and consumer awareness [6][8] Other Important Information - The company has successfully offset tariff impacts through alternate supply chain options and pricing actions [5][6] - A new microencapsulation manufacturing facility is expected to be completed by early 2027, which will double the capacity of the old plant [44][46] Q&A Session Summary Question: Can you discuss the changes in food solutions and the outlook for each subsegment in 2026? - Management noted that the Human Nutrition and Health segment saw a 14% increase in sales, with the nutrient portfolio up about 30% and food business up nearly 7%, driven by better-for-you trends [29][30] Question: What is the opportunity for product penetration and awareness of your minerals? - Management indicated that there is significant room for growth in product penetration, estimating the market opportunities to be 3 to 4 times the current size [34][35] Question: Can you comment on international anti-dumping practices and their impact? - Management discussed preliminary anti-dumping duties on China-origin choline chloride by the EU, which could create a level playing field and boost sales [40][41] Question: What is the status of the Orange County microencapsulation facility? - Management confirmed that construction is expected to be completed by early 2027, allowing for continued growth in the encapsulate business [46][47] Question: What is the expected pace of debt repayment moving forward? - Management stated that the pace of debt repayment will depend on M&A opportunities and ongoing cash flow generation [48][50]